Human Papillomavirus (HPV) Clinical Trial
Official title:
A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
The purpose of this study is to determine whether a drug called AMG 319 has an effect on a patient's own immune response to head and neck cancer squamous cell carcinoma (HNSCC). This study is specifically for patients who are having surgery to treat their HNSCC
Cancers use 'defence mechanisms' to hide from the immune system and teach the immune system
not to destroy cancer cells. AMG 319 works by blocking these defence mechanisms in the
tumour. It targets and blocks an important protein called PI3K delta.
In the laboratory this leads to removal of a group of inhibitory immune cells. Releasing the
immune brakes leads to immune attack and destruction of cancer cells.
AMG 319 looks promising in laboratory studies and in a very early study in a small number of
patients with leukaemia and we now wish to find out if it will be useful in treating patients
with head and neck cancer.
This study is a randomised, doubleblind, placebo controlled Phase II trial looking at the
effects of giving AMG 319 to patients with either human papilloma virus (HPV) positive or
negative head and neck cancer squamous cell carcinoma (HNSCC). We propose to treat patients
prior to resection surgery so that we can study the effect of AMG 319 on the cancer in fine
detail.
Approximately 54 patients with HPV positive or negative HNSCC of the hypopharynx, oropharynx,
oral cavity, supraglottis or larynx will be entered into the study. Patients will be randomly
assigned to one of two treatment groups and will receive between 20 and 29 days of oral
dosing with AMG 319 or placebo immediately before resection surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05727033 -
Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
|
N/A | |
| Completed |
NCT03111251 -
Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics
|
N/A | |
| Withdrawn |
NCT04849377 -
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
|
Phase 2 | |
| Completed |
NCT02873741 -
New Strategies to Assess Anal Cancer Risk In Women
|
||
| Completed |
NCT01188850 -
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
|
Phase 1 | |
| Completed |
NCT02524223 -
Prevalence of HPV Transmission During Medically Assisted Procreation Procedures
|
N/A | |
| Completed |
NCT03180684 -
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
|
Phase 2 | |
| Recruiting |
NCT01197079 -
Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years)
|
N/A | |
| Recruiting |
NCT05539638 -
The Role of Circulating Tumour DNA in Head and Neck Cancer
|